Spotlight – scratching the surface of the urticaria pipeline
Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
Sanofi goes back to Scribe
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
Caribou’s allogeneic Car meets a six-month bar
But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
A chronic disappointment for Viridian
Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.